EMBC
Embecta CorpNASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$547.78M
P/E Ratio
3.92
EPS
$2.36
Beta
1.05
52W High
$15.13
52W Low
$8.47
50-Day MA
$9.24
200-Day MA
$11.88
Dividend Yield
6.50%
Profit Margin
12.90%
Forward P/E
—
PEG Ratio
—
About Embecta Corp
Embecta Corp (EMBC) is a premier medical technology company specializing in innovative insulin delivery solutions for diabetes management. As a strategic spin-off from Becton, Dickinson and Company, Embecta utilizes state-of-the-art technologies and a diverse product portfolio, including insulin pens and syringes, to optimize patient care and improve health outcomes. With a strong commitment to operational excellence and a customer-centric approach, Embecta is well-positioned to seize growth opportunities in the rapidly evolving diabetes care market, aiming to enhance patient experiences while solidifying its leadership within the industry.
Fundamentals
| Revenue (TTM) | $1.08B |
| Gross Profit (TTM) | $681.90M |
| EBITDA | $366.70M |
| Operating Margin | 29.20% |
| Return on Equity | 0.00% |
| Return on Assets | 18.40% |
| Revenue/Share (TTM) | $18.45 |
| Book Value | $-10.35 |
| Price-to-Book | 2.61 |
| Price-to-Sales (TTM) | 0.51 |
| EV/Revenue | 1.611 |
| EV/EBITDA | 5.10 |
| Quarterly Earnings Growth (YoY) | 82.70% |
| Quarterly Revenue Growth (YoY) | -0.30% |
| Shares Outstanding | $59.22M |
| Float | $58.30M |
| % Insiders | 1.69% |
| % Institutions | 105.38% |
Historical Volatility
HV 10-Day
43.96%
HV 20-Day
38.43%
HV 30-Day
34.77%
HV 60-Day
34.13%
HV Rank
19.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($15.00 target)
1
Buy2
Hold1
Strong SellMore HEALTHCARE Stocks
Data last updated: 5/5/2026